Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1978 1
1979 1
1981 1
1982 1
1985 1
1987 1
1988 5
1989 4
1991 1
1993 3
1994 3
1995 2
1996 4
1997 3
1998 3
1999 5
2000 3
2001 4
2002 2
2003 1
2004 2
2005 1
2006 3
2007 4
2008 8
2009 5
2010 10
2011 8
2012 16
2013 10
2014 13
2015 11
2016 12
2017 13
2018 11
2019 12
2020 23
2021 21
2022 12
2023 14
2024 14
2025 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

254 results

Results by year

Filters applied: . Clear all
Page 1
"Discrepant low von Willebrand factor activity results on the ACL TOP analyzer are frequent in unselected patients with myeloproliferative neoplasms and show no correlation with high-molecular-weight multimer loss or bleeding phenotype": comment from Al Sharif et al.
Al Sharif MA, Harnett B, Tasneem S, Leber B, Hillis C, Hayward CPM. Al Sharif MA, et al. Among authors: leber b. J Thromb Haemost. 2025 Mar;23(3):1123-1126. doi: 10.1016/j.jtha.2024.11.017. J Thromb Haemost. 2025. PMID: 40057370 No abstract available.
A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML.
Garcia-Manero G, McCloskey J, Griffiths EA, Yee KWL, Zeidan AM, Al-Kali A, Deeg HJ, Sabloff M, Keating MM, Zhu N, Gabrail NY, Fazal S, Maly J, Odenike O, DeZern AE, O'Connell CL, Roboz GJ, Busque L, Buckstein R, Amin H, Leber B, Shastri A, Oganesian A, Keer HN, Azab M, Savona MR. Garcia-Manero G, et al. Among authors: leber b. Future Oncol. 2025 Apr;21(8):929-941. doi: 10.1080/14796694.2025.2468578. Epub 2025 Mar 6. Future Oncol. 2025. PMID: 40051275 Free PMC article.
Evaluation of infectious complications in patients with myelodysplastic syndromes: a prospective cohort study from the Canadian MDS registry.
Mathur S, Christou G, Delage R, Elemary M, Finn N, Geddes M, Houston DS, Keating MM, Khalaf D, Leber B, Leitch H, Lother SA, Mozessohn L, Nevill T, Parmentier A, Paulson K, Rimmer E, Sabloff M, Shamy A, St-Hilaire E, Storring J, Yee K, Zhang L, Zhu N, Hay AE, Zarychanski R, Buckstein R, Houston BL. Mathur S, et al. Among authors: leber b. Ann Hematol. 2024 Dec;103(12):5241-5248. doi: 10.1007/s00277-024-06096-x. Epub 2024 Nov 22. Ann Hematol. 2024. PMID: 39572410
Early Mixed Donor Chimerism is a Strong Negative Prognostic Indicator in Allogeneic Stem Cell Transplant for AML and MDS.
Radford M, Garcia-Horton A, Badami R, Jin E, Usmani N, Grafodatskaya D, McCready E, Khalaf D, Walker I, Leber B, Lepic K, Pond G, Berg T. Radford M, et al. Among authors: leber b. Transplant Cell Ther. 2025 Feb;31(2):77.e1-77.e20. doi: 10.1016/j.jtct.2024.11.006. Epub 2024 Nov 14. Transplant Cell Ther. 2025. PMID: 39547311 Free article.
Improvement in quality of life in MDS patients who become transfusion independent after treatment.
Wan BA, Alibhai SMH, Chodirker L, Mozessohn L, Geddes M, Zhu N, Trottier AM, St-Hilaire E, Finn N, Leber B, Khalaf D, Christou G, Sabloff M, Leitch HA, Shamy A, Yee KWL, Storring J, Nevill TJ, Houston BL, Elemary M, Delage R, Parmentier A, Siddiqui M, Mamedov A, Zhang L, Buckstein R. Wan BA, et al. Among authors: leber b. Leuk Lymphoma. 2025 Feb;66(2):279-288. doi: 10.1080/10428194.2024.2422844. Epub 2024 Nov 9. Leuk Lymphoma. 2025. PMID: 39520728
Development of an evidence-based hepatitis C education program to enhance public health literacy in the Australian prison sector: The Hepatitis in Prisons Education program (HepPEd).
Sheehan Y, Lafferty L, Tedla N, Byrne M, Dawson O, Stewart S, Leber B, Habraken N, Lloyd AR. Sheehan Y, et al. Among authors: leber b. Int J Drug Policy. 2024 Jul;129:104461. doi: 10.1016/j.drugpo.2024.104461. Epub 2024 Jul 5. Int J Drug Policy. 2024. PMID: 38971019 Free article.
Identification of cells of leukemic stem cell origin with non-canonical regenerative properties.
Hollands CG, Boyd AL, Zhao X, Reid JC, Henly C, ElRafie A, Boylan D, Broder E, Kalau O, Johnson P, Mark A, McNicol J, Xenocostas A, Berg T, Foley R, Trus M, Leber B, Garcia-Horton A, Campbell C, Bhatia M. Hollands CG, et al. Among authors: leber b. Cell Rep Med. 2024 Apr 16;5(4):101485. doi: 10.1016/j.xcrm.2024.101485. Epub 2024 Apr 5. Cell Rep Med. 2024. PMID: 38582086 Free PMC article.
254 results